2 days ago
18
ARTICLE AD BOX
One of the biggest challenges in cancer care is that the same therapy can be highly effective for some patients yet fail entirely for others. A new study published in Nature Communications, led by Dr. Louise Fets at the MRC Laboratory of Medical Sciences (LMS), takes a closer look at why this happens. The researchers focused on PARP inhibitors, a class of targeted cancer drugs, and tracked how they move through ovarian tumor samples using advanced imaging tools.
English (US) ·